SCNI
Scinai Immunotherapeutics Ltd.
Related News
SEC Filings
Earnings Trend
Screening
Compare
Economic Calendar
We use cookies in accordance with European GDPR standards to improve site usability, analytics, and deliver personalized advertising.Learn moreCookie Settings
Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding
